www.aptinyx.com Open in urlscan Pro
64.225.94.43  Public Scan

Form analysis
1 forms found in the DOM

GET https://www.aptinyx.com/

<form role="search" action="https://www.aptinyx.com/" class="qode_search_form_2" method="get">
  <div class="container">
    <div class="container_inner clearfix">
      <div class="form_holder_outer">
        <div class="form_holder">
          <input type="text" placeholder="Search" name="s" class="qode_search_field" autocomplete="off">
          <a class="qode_search_submit" href="javascript:void(0)">
<i class="qode_icon_font_awesome fa fa-search "></i>		</a>
        </div>
      </div>
    </div>
  </div>
</form>

Text Content

 * Our Approach
    * Our Approach
    * NMDA Receptors
    * Therapeutic Area Focus

 * Pipeline
    * Publications

 * Clinical Studies
 * Investors & Media
    * Press Releases
    * Events & Presentations
    * Stock Information
    * Financials & Filings
    * Governance
    * FAQs and Contacts

 * About Us
    * About Aptinyx
    * Leadership
    * Board of Directors
    * Scientific Advisory Board
    * Working at Aptinyx
    * Contact Us

 * Our Approach
   * Our Approach
   * NMDA Receptors
   * Therapeutic Area Focus
 * Pipeline
   * Publications
 * Clinical Studies
 * Investors & Media
   * Press Releases
   * Events & Presentations
   * Stock Information
   * Financials & Filings
   * Governance
   * FAQs and Contacts
 * About Us
   * About Aptinyx
   * Leadership
   * Board of Directors
   * Scientific Advisory Board
   * Working at Aptinyx
   * Contact Us

Discovering & Developing Innovative Therapies for Challenging Disorders of the
Brain & Nervous System


OUR COMPANY

Discovering and developing innovative therapies for patients with challenging
brain and nervous system disorders.
LEARN MORE


OUR PLATFORM

Producing therapies with novel chemistry that modulate NMDA receptors, which are
vital to normal brain physiology, and restore normal balance in the brain & CNS
LEARN MORE


OUR DEVELOPMENT PROGRAMS

Advancing development candidates across post-traumatic stress disorder,
cognitive impairment, and opioid use disorder
LEARN MORE




LATEST NEWS



August 25, 2022
Aptinyx Completes Enrollment in Phase 2 Study of NYX-458 in Cognitive Impairment
Associated with Parkinson’s Disease and Dementia with Lewy Bodies




August 12, 2022
Aptinyx Reports Results from Phase 2b Study of NYX-2925 in Fibromyalgia

























August 4, 2022
Aptinyx Reports Second Quarter 2022 Financial Results and Recent Highlights







View All News


© 2022 Aptinyx Inc.    |    Terms of Use    |    Privacy Policy     |
   909 Davis Street, Suite 600, Evanston, IL 60201
http://premier-pharmacy.com/product-category/pain-relief/ http://healthsavy.com
https://viagragener.com